# The role of Huntingtin in endolysosomal trafficking and Huntington's disease pathogenesis

> **NIH NIH F99** · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · 2024 · $38,124

## Abstract

PROJECT SUMMARY
With no effective treatments or cures, ageing-related neurodegenerative diseases (NDs) present a pressing
threat to our society. Converging evidence links NDs to defects in endolysosomal trafficking, a vital cellular
process used by neurons to maintain their tidiness during normal aging. As one of the most extensively studied
NDs, autosomal dominant Huntington's disease (HD) is caused by an abnormal expansion of CAG repeats in
the coding region of the Huntingtin (HTT) gene that leads to an abnormally long polyglutamine (polyQ) tract in
the corresponding encoded HTT protein. This results in a dominant neurotoxicity and potential alterations of
HTT’s normal physiological functions that together lead to the selective loss of medium spiny and cortical
projection neurons in the brain. Interestingly, defective endolysosomal trafficking has been observed in HD, and
HTT itself has been implicated in endosomal pathways from many in vitro studies. However, whether and how
HTT functions in endolysosomal pathways in a physiologic condition remains unexplored. HTT forms a tight
complex with its cognate binding partner HAP40, both of which are conserved in the model organism Drosophila.
By characterizing these two genes in Drosophila, I found in vivo evidence that HAP40 controls HTT in regulating
the functional convergence of endolysosomal recycling and degradation. Together with other evidence, they led
to my central hypothesis that through HAP40, HTT regulates Rab4 and Rab4-mediated endolysosomal
trafficking, a cellular process potentially disrupted by polyQ expansion in HD. For the F99 dissertation stage, I
propose to elucidate the molecular mechanism and functional consequence of this novel HTT/HAP40-mediated
endosomal trafficking by harnessing the power of multiple complementary model systems, including genetics
and genomics in fruit flies, live/super-resolution imaging in mammalian cells, and brain structure and function
analysis in mice (Aim1). Results from this study will define a novel and conserved role of HTT in endolysosomal
processes, uncover its underlying mechanism, and its physiological importance. For the K00 post-doctoral stage,
I plan to continue this direction of research but expand my training to new technologies such as human induced
pluripotent stem cells (hiPSC)/brain organoids that are more related to humans and with more direct translational
potential, complemented with more systematic training in mouse ND models, to study endolysosomal pathways
such as the Retromer complex that are implicated in more prevalent NDs including Parkinson’s (PD) and
Alzheimer’s (AD) diseases. My goals are to understand how endolysosomal pathways contribute to different NDs
and whether membrane trafficking pathways can be targeted as novel effective therapeutic avenue to treat NDs
(Aim2). For both the F99 and K00 stages, I plan to devote extensive effort towards research training and
professional development. Overall, the proposed study wil...

## Key facts

- **NIH application ID:** 11075519
- **Project number:** 1F99NS141400-01
- **Recipient organization:** UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- **Principal Investigator:** Stephen M Farmer
- **Activity code:** F99 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $38,124
- **Award type:** 1
- **Project period:** 2024-09-18 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11075519

## Citation

> US National Institutes of Health, RePORTER application 11075519, The role of Huntingtin in endolysosomal trafficking and Huntington's disease pathogenesis (1F99NS141400-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/11075519. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
